In the current study, we assessed the concentrations of CSF PGRN and NFL in RIS patients as potential markers of early repair mechanisms/inflammation and axonal loss, to compare them with the CSF PGRN and NFL concentrations in controls and patients at different MS disease stages and with different MS subtypes. This evidence concerns the gene NEFL and myeloid sarcoma.